Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan 28 March 2022
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. 4 March 2022
Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico 18 February 2022
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes 14 January 2022
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements 21 December 2021
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQTM (infigratinib) in Canada 21 December 2021
The 3rd Sustainability Report confirms IBSA’s commitment to the well-being of the Person 20 December 2021
Linkedin